Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
双价肾综合征出血热灭活疫苗（Vero细胞）
- Development stage
- Unknown
- Lead developer
- 罗益
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**双价肾综合征出血热灭活疫苗（Vero细胞）** is a bivalent, whole-virus inactivated vaccine developed and manufactured by Wuxi Royal Biological for prevention of hemorrhagic fever with renal syndrome. The product contains two inactivated hantavirus valents associated with HFRS. The viral materials are cultured, inactivated with beta-propiolactone, purified, and combined into a bivalent vaccine intended to induce protective humoral immune responses against HFRS-associated hantaviruses.
- Other names
- 出血热疫苗双价肾综合征出血热灭活疫苗
02
Targets
SEOV (Seoul orthohantavirus)HTNV (Hantaan orthohantavirus)
Beyond the preview
Go deeper on 双价肾综合征出血热灭活疫苗（Vero细胞）.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 双价肾综合征出血热灭活疫苗（Vero细胞）.